Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash from Financing Activities (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Cash from Financing Activities for 10 consecutive years, with $394.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 13285.13% to $394.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $478.0 million, a 19.8% increase, with the full-year FY2025 number at $478.0 million, up 19.8% from a year prior.
  • Cash from Financing Activities was $394.2 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $2000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $491.9 million in Q3 2022 to a low of -$722000.0 in Q1 2023.
  • A 5-year average of $94.2 million and a median of $11.9 million in 2021 define the central range for Cash from Financing Activities.
  • Biggest YoY gain for Cash from Financing Activities was 17459.4% in 2023; the steepest drop was 144.79% in 2023.
  • Ultragenyx Pharmaceutical's Cash from Financing Activities stood at $85.7 million in 2021, then crashed by 97.8% to $1.9 million in 2022, then surged by 17459.4% to $330.5 million in 2023, then plummeted by 99.11% to $2.9 million in 2024, then surged by 13285.13% to $394.2 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Cash from Financing Activities are $394.2 million (Q4 2025), $2000.0 (Q3 2025), and $83.6 million (Q2 2025).